Vascular access decision simulator — weighing native arteriovenous fistula against synthetic PTFE graft for hemodialysis access planning
Vascular access guidelines built around the "Fistula First" philosophy hold that, whenever anatomy permits, a native arteriovenous (AV) fistula should be the initial choice for hemodialysis access. Created by directly joining an artery to an adjacent vein — most commonly radiocephalic at the wrist or brachiocephalic at the elbow — the fistula uses the patient's own tissue, which remodels under arterial flow into a durable, high-flow conduit that can serve for years with relatively few interventions.
A surgeon anastomoses an artery directly to a nearby superficial vein, most commonly:
• Radiocephalic (wrist): artery and cephalic vein joined at the wrist — the most distal option, preserving vessels higher up the arm for future access • Brachiocephalic (elbow): used when wrist vessels are too small • Brachiobasilic (with vein transposition): the basilic vein is surgically relocated closer to the skin for easier cannulation
Once connected, arterial pressure and flow are diverted into the vein. Over subsequent weeks, the vein undergoes "arterialization" — its wall thickens, its diameter enlarges, and flow through it rises substantially above baseline venous flow. This remodeled vein becomes the conduit that is repeatedly cannulated for dialysis, cycle after cycle, for years.
A living, remodeling vein has properties a synthetic tube cannot fully replicate:
• Self-healing endothelium: the vein's inner lining can repair minor injury from repeated needle sticks, reducing scar buildup at cannulation sites • Biological integration: no foreign material for the immune system to react to, translating into markedly lower infection rates • Compliance: the vessel wall flexes with pressure changes rather than presenting a rigid interface prone to turbulence and clot formation • Durability: once matured, a well-functioning fistula frequently remains usable for many years with fewer revision procedures than a graft
These properties are the basis for guideline bodies consistently ranking the fistula above the graft whenever the patient's vascular anatomy makes it feasible.
Because a fistula's advantages depend entirely on suitable native vessels, the decision to pursue a fistula versus a graft begins with a careful anatomical assessment — the subject of the next stage.
Not every patient has vessels capable of sustaining a fistula. Small or sclerotic veins, weak or diseased arterial inflow, and vessels scarred or thrombosed from prior IV lines, catheters, or failed access attempts can all make fistula creation impractical or doomed to early failure. Preoperative vessel mapping — typically duplex ultrasound, sometimes supplemented by venography — is used to systematically evaluate candidacy before committing to a surgical plan.
Before any access surgery, clinicians assess both sides of the anastomosis:
Venous evaluation: • Diameter along the length of the vein — a vein must be large enough, and consistently so, to dilate under arterial pressure without segments too narrow to mature • Continuity and patency — no occluded or heavily scarred segments from previous cannulation, PICC lines, or central catheters • Depth from the skin surface — veins too deep are harder to cannulate reliably even if they mature well
Arterial evaluation: • Inflow diameter and quality of pulsatile flow — weak or calcified arterial inflow will not deliver enough pressure/flow to arterialize a downstream vein • Continuity to more proximal vessels in case a more central anastomosis is needed
When either side of this equation fails to meet suitability thresholds, fistula creation is likely to fail to mature or to fail early, and a synthetic graft becomes the more realistic option.
Several patient factors commonly compromise vessel suitability:
• Repeated venipuncture and prior IV access: routine blood draws and IV lines over a patient's lifetime — especially in those with long histories of hospitalization — can scar and narrow superficial veins • Prior central venous catheters: dialysis catheters and central lines can cause central vein stenosis or thrombosis, compromising outflow even when the peripheral vein itself looks adequate • Peripheral arterial disease: calcified, narrowed arteries — more common with diabetes and advanced age — reduce the inflow needed to arterialize a fistula • Small body habitus or anatomic variation: some patients simply have naturally small-caliber vessels throughout • "Vessel-exhausted" patients: those who have already undergone multiple failed access attempts may have depleted the usable superficial vein sites on both arms
When these factors converge, the surgical team must decide whether to attempt a more proximal or transposed fistula, or move directly to graft placement.
Recognizing an unsuitable vessel before surgery — rather than after a failed fistula attempt — spares the patient a wasted procedure and preserves remaining vessels for a future access attempt.
When native vessels cannot support a fistula, an arteriovenous graft substitutes a synthetic conduit — most commonly expanded polytetrafluoroethylene (ePTFE) — surgically connected between an artery and a vein. Because the conduit is manufactured rather than grown from the patient's own tissue, surgeons have far more flexibility in how it is routed, which can be a decisive advantage when anatomy is difficult.
Expanded polytetrafluoroethylene became the dominant graft material because it combines several practical properties:
• Biocompatibility: well tolerated by surrounding tissue with a manageable, if higher-than-fistula, infection profile • Handling characteristics: the material is easy for surgeons to suture and tunnel subcutaneously • Self-sealing after needle puncture: repeated cannulation does not require an external patch or plug, since the graft wall closes around the needle tract • Manufactured consistency: unlike native vessels, every graft segment has the same diameter and wall properties, removing anatomic variability from the equation
Other materials — bovine carotid artery grafts, biosynthetic or bioengineered conduits — are used in select circumstances (for example, after graft infection, where reduced infection susceptibility is prioritized), but ePTFE remains the default choice in most centers.
Because the conduit is synthetic tubing rather than a fixed vessel, it can be shaped to the patient's anatomy:
• Straight configuration: the graft runs a direct line between the artery and a vein, typically used in the forearm when a nearby artery and vein are both accessible and reasonably close together • Looped configuration: the graft is tunneled in a U-shape, most often in the upper arm or thigh, when the artery and vein used for anastomosis are positioned such that a direct line is not practical, or when a longer cannulation surface is desirable
The choice between straight and looped is driven by the specific arterial and venous sites available, the amount of subcutaneous tunneling space, and the surgeon's assessment of which configuration will offer the most durable, easily cannulated segment over the graft's lifespan.
Because the conduit itself is manufactured, its shape can be adapted to anatomy that would never support a native fistula — the core reason grafts remain a viable and important fallback option.
One of the graft's clearest practical advantages is speed: because it is already a finished, full-diameter conduit at the time of surgery, it does not need to remodel the way a native vein does. Fistulas, by contrast, require a maturation period during which the vein must dilate and thicken before it can safely tolerate repeated needle cannulation — a real tradeoff when dialysis is needed soon.
A newly created fistula is, at first, simply a vein carrying arterial pressure it was never built for. Over subsequent weeks, this vein must:
• Dilate to a larger internal diameter, wide enough to be safely and repeatedly punctured with large-bore dialysis needles • Thicken its wall in response to the higher pressure, reducing the risk of blowouts, aneurysm formation, or infiltration during cannulation • Increase flow sufficiently to support the volumes needed for an effective dialysis session
Clinicians commonly reference a rough "rule of 6s" heuristic when judging maturation readiness — looking for the vein to reach roughly 6mm diameter, sit within about 6mm of the skin surface, and carry roughly 600mL/min of flow — though practice varies and ultrasound assessment is used to confirm readiness on an individual basis. Attempting to cannulate before adequate maturation risks infiltration, hematoma, and fistula failure.
A synthetic graft arrives at surgery already at its full, fixed diameter — there is no biological remodeling required before it can, in principle, be punctured. Standard ePTFE grafts are typically allowed to heal for a couple of weeks to let the surgical tunnel incorporate the graft and reduce the risk of perigraft hematoma, but this is a much shorter wait than fistula maturation.
Specialized early-cannulation graft materials go further, engineered with self-sealing multilayer walls that tolerate needle puncture within a day or two of implantation — designed specifically for patients who cannot wait weeks for any other access to become usable.
This is why grafts are frequently chosen — even in patients whose vessels might otherwise support a fistula — when dialysis cannot reasonably be delayed and a temporary catheter is being avoided or needs to be removed quickly.
The time-to-use advantage of grafts is real, but it is a tradeoff, not a free win: the same manufactured conduit that lets a graft be used sooner is also the reason it tends to wear out faster than a fistula, as the next stage examines.
The decision between fistula and graft is ultimately a bet on the years ahead, not just the weeks after surgery. Followed over time, fistulas generally sustain better patency with fewer thrombotic and infectious events, while grafts more frequently develop stenosis — especially at the venous anastomosis — and tend to have a shorter overall functional lifespan, often requiring more interventions to keep them working.
The point where a synthetic graft meets the native vein experiences turbulent, non-physiologic flow conditions — a mismatch in compliance between rigid synthetic material and elastic vein tissue. Over time this promotes intimal hyperplasia: smooth muscle cells and connective tissue proliferate at the junction, progressively narrowing the outflow tract.
As this venous anastomosis stenosis worsens, flow through the graft drops, resistance rises, and the risk of thrombosis increases sharply. This single complication is responsible for a large share of graft revision procedures — angioplasty, stenting, or surgical revision — needed to keep a graft functioning over its lifespan.
Native fistulas can also develop stenosis, but the biological, compliant nature of an all-native anastomosis makes this less frequent and often less severe than at a synthetic-to-native junction.
Because a graft introduces permanent foreign material into the body, it carries a persistently higher infection risk than a fistula across its functional life — repeated needle punctures into synthetic material provide more opportunity for bacterial seeding than punctures into living, self-healing vein tissue. Graft infections can be more difficult to manage, sometimes requiring partial or complete graft excision, whereas fistula infections are comparatively less common and often more manageable.
This elevated infection risk, compounded over months and years of repeated cannulation, is one of the central reasons long-term patency and complication profiles diverge so clearly between the two access types.
Across the stages of this simulator, the decision between fistula and graft comes down to balancing four factors:
• Vessel suitability — does the patient have vein and artery quality adequate for a fistula to mature successfully? • Urgency — can the patient wait weeks to months for maturation, or is dialysis access needed sooner? • Time horizon — is this likely to be a long-term access strategy, favoring the durability of a fistula, or a bridging solution? • Vessel preservation — even when a graft is chosen now, preserving remaining native vessels keeps the door open for a future fistula attempt
No single factor decides the choice in isolation; clinical teams weigh all of them together, guided by vessel mapping, patient urgency, and long-term dialysis planning.
Guideline bodies consistently frame this as a hierarchy, not a rigid rule: attempt a fistula when anatomy and timeline allow it, and reserve the graft for patients whose vessels or urgency make a fistula impractical — a strategy aimed at maximizing years of reliable, complication-free dialysis access.